Leflunomide Elvim (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, which is essential for pyrimidine synthesis in rapidly dividing lymphocytes. By limiting lymphocyte proliferation, it dampens the immune response that drives inflammation in rheumatoid and psoriatic arthritis.

The dosing regimen for Leflunomide Elvim is determined by the prescribing physician based on the individual’s clinical status, renal and hepatic function, and concomitant therapies. Physicians typically start with a loading dose followed by a maintenance dose, but exact amounts are not disclosed here.

Leflunomide is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations. It is also not recommended for breastfeeding mothers because it can be excreted in breast milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The most common alternative to Leflunomide is methotrexate, another DMARD. While both suppress immune activity, Leflunomide is taken orally and may be preferred when methotrexate intolerance occurs. However, Leflunomide carries a higher risk of liver toxicity and is contraindicated in pregnancy, whereas methotrexate has its own teratogenic risks.

Leflunomide Elvim tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

The medication is administered orally as a tablet, usually swallowed whole with a glass of water. It can be taken with or without food, but consistent timing each day helps maintain stable blood levels. Patients should follow the prescribing physician’s instructions regarding dosage and schedule.

Serious risks include severe liver injury, pulmonary toxicity (such as interstitial lung disease), bone‑marrow suppression leading to low blood counts, and teratogenic effects if pregnancy occurs. Patients should report signs of jaundice, persistent cough, unexplained bruising, or any pregnancy‑related concerns immediately.

Leflunomide Elvim should not be used by pregnant women, individuals with severe hepatic impairment, patients with active serious infections, or those who cannot use effective contraception. It is also contraindicated in patients with known hypersensitivity to Leflunomide or its excipients.